Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Patricio López-Jaramillo; Carlos Velandia; Gabriela Castillo; Tatiana Sánchez; Julie Álvarez

doi:10.1016/s0120-5633(13)70072-x

Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Título traducido de la contribución: Análogos de incretina e inhibidores de la DPP-4: ¿qué papel desempeñan en la prevención primaria de las enfermedades cardiovasculares?

Patricio López-Jaramillo
, Carlos Velandia
, Gabriela Castillo
, Tatiana Sánchez
, Julie Álvarez

Producción científica: Artículos / Notas › Articulo en revista no especializada › revisión exhaustiva

4 Citas (Scopus)

Resumen

Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

Título traducido de la contribución	Análogos de incretina e inhibidores de la DPP-4: ¿qué papel desempeñan en la prevención primaria de las enfermedades cardiovasculares?
Idioma original	Inglés
Páginas (desde-hasta)	287-299
Número de páginas	13
Publicación	Revista Colombiana de Cardiologia
Volumen	20
N.º	5
DOI	https://doi.org/10.1016/s0120-5633(13)70072-x
Estado	Publicada - 2013
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/s0120-5633(13)70072-x

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{8881c617150644ec8c5b0db695b4ea30,

title = "Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?",

abstract = "Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70\% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.",

keywords = "Cardiovascular disease, Diabetes, Inhibitors, Pharmacology",

author = "Patricio L{\'o}pez-Jaramillo and Carlos Velandia and Gabriela Castillo and Tatiana S{\'a}nchez and Julie {\'A}lvarez",

year = "2013",

doi = "10.1016/s0120-5633(13)70072-x",

language = "Ingl{\'e}s",

volume = "20",

pages = "287--299",

journal = "Revista Colombiana de Cardiologia",

issn = "0120-5633",

publisher = "Permanyer Publications",

number = "5",

}

Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases? / López-Jaramillo, Patricio; Velandia, Carlos; Castillo, Gabriela et al.
En: Revista Colombiana de Cardiologia, Vol. 20, N.º 5, 2013, p. 287-299.

Producción científica: Artículos / Notas › Articulo en revista no especializada › revisión exhaustiva

TY - JOUR

T1 - Incretin analogs and inhibitors of DPP-4

T2 - Which is their role in the primary prevention of cardiovascular diseases?

AU - López-Jaramillo, Patricio

AU - Velandia, Carlos

AU - Castillo, Gabriela

AU - Sánchez, Tatiana

AU - Álvarez, Julie

PY - 2013

Y1 - 2013

N2 - Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

AB - Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

KW - Cardiovascular disease

KW - Diabetes

KW - Inhibitors

KW - Pharmacology

UR - https://www.scopus.com/pages/publications/84896738406

U2 - 10.1016/s0120-5633(13)70072-x

DO - 10.1016/s0120-5633(13)70072-x

M3 - Articulo en revista no especializada

AN - SCOPUS:84896738406

SN - 0120-5633

VL - 20

SP - 287

EP - 299

JO - Revista Colombiana de Cardiologia

JF - Revista Colombiana de Cardiologia

IS - 5

ER -

Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto